New Combination Approaches to Enhance Rituximab-based Lymphoma Therapies Books

Click Get Book Button To Download or read online New Combination Approaches to Enhance Rituximab-based Lymphoma Therapies books, Available in PDF, ePub, Tuebl and Kindle. This site is like a library, Use search box in the widget to get ebook that you want.

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies


New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies
  • Author :
  • Publisher : Academic Press
  • Release : 2020-07-15
  • ISBN : 0128164077
  • Language : En, Es, Fr & De
GET BOOK

New Combination Approaches to Enhance Rituximab-based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Journal of the National Cancer Institute


Journal of the National Cancer Institute
  • Author :
  • Publisher :
  • Release : 2002
  • ISBN : UCR:31210015965740
  • Language : En, Es, Fr & De
GET BOOK

Yonsei Medical Journal


Yonsei Medical Journal
  • Author :
  • Publisher :
  • Release : 2007
  • ISBN : MINN:31951P01070862B
  • Language : En, Es, Fr & De
GET BOOK

Perry s The Chemotherapy Source Book


Perry s The Chemotherapy Source Book
  • Author : Michael C. Perry
  • Publisher : Lippincott Williams & Wilkins
  • Release : 2012-07-30
  • ISBN : 9781469803432
  • Language : En, Es, Fr & De
GET BOOK

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy


Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy
  • Author : Patrik Andersson
  • Publisher : Frontiers Media SA
  • Release : 2019-12-27
  • ISBN : 9782889631612
  • Language : En, Es, Fr & De
GET BOOK

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.